CommercialPrior AuthHigh impact
State and School Employees' Health Insurance Plan - Rituximab Non-Oncology
Blue Cross & Blue Shield of Mississippi·MS · Rheumatology, Neurology, Nephrology +3 more·Medical Policy
We identified it
Jun 20, 2026
Summary
New policy establishes comprehensive prior authorization and coverage criteria for rituximab biosimilars (Ruxience and Truxima) for non-cancer conditions including rheumatoid arthritis, autoimmune disorders, and multiple sclerosis. The policy requires specific diagnostic criteria, failed conventional therapy trials, and specialist consultation for approval.
Action Required
Immediately: Billing team must implement prior authorization requirements for all rituximab biosimilar claims (Ruxience and Truxima) for non-oncology indications. Update billing system to flag these drugs for prior auth verification. Providers must document specific diagnostic criteria, previous treatment failures, hepatitis B screening results, and specialist consultation before administration. Claims will be denied without proper prior authorization and documentation.